EICHOR
● Active Not Recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Condition: Ischemic Stroke; Ischemic Attack, Transient · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (880)
| Banner Desert Medical Center | Mesa, Arizona, United States | — |
| University of Arizona | Tucson, Arizona, United States | — |
| Plaza Neuroscience Clinic | Fayetteville, Arkansas, United States | — |
| Alta Bates Medical Center Cancer Center | Berkeley, California, United States | — |
| Providence Saint Joseph Medical Center - Cancer Center | Burbank, California, United States | — |
| Mills Peninsula Health Services | Burlingame, California, United States | — |
| Sutter Health - Eden Medical Center | Castro Valley, California, United States | — |
| Neurology Center of North Orange County | Fullerton, California, United States | — |
| Glendale Adventist Medical Center | Glendale, California, United States | — |
| UC Irvine Healthcare Center | Irvine, California, United States | — |
| Sharp Grossmont Hospital | La Mesa, California, United States | — |
| Long Beach Memorial | Long Beach, California, United States | — |
+ 868 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.